3 citations
,
November 2024 in “Clinical Research” Deuruxolitinib is FDA-approved for treating severe alopecia areata.
53 citations
,
July 2018 in “Drug design, development and therapy” Janus kinase inhibitors show promise in treating alopecia areata but need better topical formulations.
40 citations
,
July 2011 in “The journal of clinical hypertension” Hydralazine and minoxidil are blood pressure medications that relax blood vessels, with potential side effects like rapid heartbeat and fluid retention, and are used for severe or pregnancy-related hypertension.
31 citations
,
January 2016 in “Drugs - Real World Outcomes” Some new oral anticoagulants may also cause hair loss and might not be better than traditional ones for preventing hair loss.
Self-monitoring blood pressure in pregnant women didn't improve outcomes, diabetes drugs may increase gallbladder disease risk, a new drug helps severe hair loss, a plant-based COVID-19 vaccine is 69.5% effective, and new anticoagulants are safer for diabetics with heart rhythm issues than warfarin.
63 citations
,
March 2001 in “Fertility and Sterility” Diane 35 plus finasteride is more effective for treating hirsutism.
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.
May 2025 in “Journal of Craniofacial Surgery Open” High-intensity focused ultrasound improved hair growth in a woman with no side effects.
December 2024 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Deucravacitinib helped a man regrow hair significantly.
19 citations
,
September 2013 in “Psychoneuroendocrinology” Blocking CYP17A1 enzyme may help improve certain brain function issues related to dopamine.
April 2026 in “Journal of the American Academy of Dermatology” Oral 5-alpha-reductase inhibitors for hair loss don't increase heart risk.
19 citations
,
September 2011 in “Journal of Dermatological Science” TGF-β1 increases androgen receptor activity in hair loss, but Hic-5/ARA55 can counter this effect.
3 citations
,
February 2010 in “Clinical kidney journal” Combining ciclosporin and simvastatin can cause severe kidney damage.
17 citations
,
May 1998 in “Steroids” Researchers developed a model to predict how well certain compounds can block an enzyme related to hair loss and prostate issues, suggesting a 50 mg dose of finasteride might be effective based on lab and body data.
27 citations
,
December 2015 in “Mayo Clinic Proceedings” The document concludes that lifestyle changes and medical treatments can significantly reduce symptoms of Hidradenitis Suppurativa, a chronic skin condition.
Dutasteride may become the top choice for treating hair loss.
June 2026 in “Journal of health economics and outcomes research” Ritlecitinib is more effective and cheaper than baricitinib for treating severe alopecia areata.
August 2019 in “Journal of the American Academy of Dermatology” Tofacitinib may help hair regrowth in alopecia areata, but more research is needed.
January 2026 in “Skin Health and Disease” Irish dermatologists use JAK inhibitors for alopecia areata but want standardized treatment guidelines.
September 2017 in “Journal of Investigative Dermatology” HIF-1A may aid hair growth, Backhousia citriodora improves skin, autologous cells stabilize hair loss, infrared thermography assesses alopecia, and a new treatment preserves hair.
16 citations
,
March 2022 in “Clinica Chimica Acta” Idiopathic hirsutism may be linked to increased enzyme activity.
39 citations
,
June 2023 in “Frontiers in Medicine” Calcium Hydroxylapatite may help skin regeneration and improve skin appearance.
June 2021 in “DOAJ (DOAJ: Directory of Open Access Journals)” JAK inhibitors show promise for treating alopecia areata but their effectiveness and safety are still debated.
February 2025 in “Canadian Journal of Health Technologies” Baricitinib is effective and cost-efficient for treating severe alopecia areata in adults.
19 citations
,
April 2020 in “Dermatologic Therapy” Dutasteride works better than finasteride for hair loss, with both being safe to use.
2 citations
,
December 2020 in “American Journal of Dermatological Research and Reviews” The combination therapy was effective and well-tolerated, especially in young patients.
June 2023 in “British Journal of Dermatology” Baricitinib was effective and safe for severe hair loss treatment over 6 months.
Deucravacitinib improves symptoms and reduces inflammation in Lichen Planopilaris.
4 citations
,
October 2024 in “Journal of the American Academy of Dermatology” Abrocitinib may help treat alopecia areata effectively with mild side effects.
June 2022 in “Value in Health” Adding Baricitinib for severe alopecia areata will have a small impact on a health plan's budget.